Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


A Model Intervention: Aiming for HCV Elimination in HIV-Positive MSM

In this podcast, learn from expert faculty as they discuss key lessons from their own micro-elimination program designed to prevent HCV transmission among HIV-positive men who have sex with men.
Dominique Laurent Braun, MD
Released: April 27, 2022

In this podcast, Dr Dominique Laurent Braun discusses his micro-elimination program, the Swiss HCVree trial, designed to prevent hepatitis C virus (HCV) transmission among HIV-positive men who have sex with men. The study employed a test-and-treat approach to eliminate HCV infection in this key target population and could be a model for other countries to eliminate HCV infection in certain populations.

Information on this Educational Activity


Dominique Laurent Braun, MD
Senior Staff Physician
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
University of Zurich
Zurich, Switzerland
Dominique Laurent Braun, MD, has received consulting fees from AbbVie, Gilead Sciences, Merck, and ViiV.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.

Related Content

Expert selections of important viral hepatitis data from AASLD 2022, including studies of patients with HBV, HDV, and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Stefan Zeuzem, MD Released: November 16, 2022

Expert summaries of key data in older patients with HBV, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Nancy Reau, MD Released: November 16, 2022

Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in China, from Clinical Care Options (CCO)

person default Dee Lee person default Jie Li, MD, PhD Released: October 4, 2022

Dr Nancy Reau on exciting viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Released: July 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings